Helen Of Troy Limited
$1.45B- Market cap
- $661.49M
- Debt
- +$810.54M
- Cash
- −$18.89M
Capital structure 45% equity / 55% debt · EV / Revenue 0.81x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HELE stock price at discount vs AVTX $28.40 current versus $1.34M implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AVTX's multiple
Implied fair value · at HELE's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HELE FY 2026 (ended Feb 28, 2026) · AVTX FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 45% equity / 55% debt · EV / Revenue 0.81x
Capital structure 101% equity / -1% debt · EV / Revenue 15725.35x
HELE carries the larger enterprise value at $1.45B against $927.80M; HELE trades on the lower EV / Revenue multiple (0.81x vs 15725.35x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HELEN OF TROY LIMITED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
AVALO THERAPEUTICS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.02x
-0.06x
Net debt / EBITDA
Leverage against operating earnings
-1.10x
1.33x
Cash and equivalents
Liquid reserves on the balance sheet
$18.89M
$98.34M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEWELL BRANDS INC.
HELE vs NWL
IROBOT CORP
HELE vs IRBT
Spectrum Brands Holdings, Inc.
HELE vs SPB
GARMIN LTD
HELE vs GRMN
CytomX Therapeutics, Inc.
HELE vs CTMX
IDEAYA Biosciences, Inc.
HELE vs IDYA
Ocugen, Inc.
HELE vs OCGN
CLOVER HEALTH INVESTMENTS, CORP. /DE
HELE vs CLOV
Citius Pharmaceuticals, Inc.
HELE vs CTXR
$810.54M
-$5.17M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.